Orforglipron

Eli Lilly Briefly Hits $1 Trillion as GLP-1 Boom Spurs Fresh Analyst Targets

Analyst upgrades highlight expectations for policy-driven access gains, with an oral GLP-1 filing seen as the next catalyst.